Oncoshot

Exciting news! We are thrilled to announce an upcoming webinar based on Omico's recent publication in npj Precision Oncology titled, "Precision Medicine: Affording the Successes of Science."

Join our esteemed panel of experts from Omico and Oncoshot as they propose an alternative, integrated model in which hospitals and industry share the risks and benefits of drug development. Featuring:

Prof David Thomas, CEO of Omico, Australia
Dr Vera Terry, Deputy CEO of Omico, Australia
Prof Christine Lu, Chair of Clinical Pharmacy at the University of Sydney, Australia
A/Prof Tam C. Nguyen, Director of Operations (Australia), Oncoshot

Some of the topics that will be covered in the webinar include:
• Current Global and Australian Landscape of Genomic Medicine
• Cancer Genomic Medicine; Value of Genomics in Healthcare
• Economic Benefits of Precision Medicine
• Drug Development Challenges
• Opportunities and Future Directions

This is a unique opportunity to gain a deeper understanding of the cutting-edge research presented in the journal article and engage with our panellists in a dynamic and interactive forum. We believe that this webinar will be of great interest to those employed in hospitals and industry, researchers, students, policymakers, and anyone interested in the latest advancements in precision medicine.

The webinar will be held on 20 April 2023 at 8am (SGT)/10am (AEST)/5pm (PDT) for 45mins. Register for free or find out more at:

https://us02web.zoom.us/.../171.../WN_g-dd6jY_ShGcw6F7VXiuvQ

We thank Economist Impact events for inviting Oncoshot to speak at the insightful Future of Healthcare Week. We hope our CEO's sharing during his Future of Cancer Care panel discussion sparks conversation and action to accelerate digital transformation.

Dr Huren Sivaraj, together with Prof Chow and Ms Mary Hemrajani, discussed several points this afternoon:

1. The impact of COVID on cancer care and policy across the globe.

Here Dr Huren shared varying examples, including the development of consensus-based guidelines for the continuation of cancer care in Malaysia and India, as well as the acceleration of data-sharing models in ecosystems such as the EU and Ontario Health Data System.

2. Exploring gaps in care from the perspective of governments, healthcare systems and patients.

3. Need for patient centricity and patient empowerment.

4. Need to focus on primary care empowerment for early cancer diagnosis and treatment.

5. How policy and technology facilitate data-driven analytics and decision making will play a foundational role in improving cancer care, access to treatment and eventually better outcomes.

In case you missed it, we signed a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre last week!

This partnership will create opportunities for global trial sponsors to leverage real-time aggregated patient insights with biomarker data and present Omico and its network of hospitals as preferred site partners within the region. More details: https://www.oncoshot.com/blog/384fbf50490844a4b56d3208f6a65757

Oncoshot is happy to announce our fundraise with the SEA Venture arm of MassMutual. With the support of Mass Mutual and other investors, Oncoshot will be extending its platform to hospitals in India and Australia for the benefit of cancer patients and the research programs within those centres. The funding will also contribute to increasing our team’s capacity and establishing strategic partnerships.



https://www.oncoshot.com/blog/d86fcac12c804582ae6853a5cb016bdd

Oncoshot is pleased to welcome A/Prof Tam C. Nguyen to the team. As Oncoshot is expanding into Australia, A/Prof Tam will be instrumental in spearheading this operation whilst driving hospital and industry collaborations down under as the new Director of Operations (Australia). Presently, he also serves as the Deputy Director of Research at St. Vincent’s Hospital Melbourne and has done so for the past eight years.

Dr Huren Sivaraj, medical oncologist and Oncoshot CEO and Co-Founder, is thankful to have Prof Tam onboard. “A/Prof Tam is a respected leader in the Australian clinical trials landscape. We are privileged to have his active participation in shaping the value proposition of the Oncoshot platform for the benefit of healthcare systems and industry stakeholders in Australia.”

"Milltrust Ventures is proud to be an investor for Oncoshot. We see the value this health insights platform can bring to the field of cancer clinical trials globally and Oncoshot's potential in bringing this system to fruition," said Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures."

Milltrust Ventures to Invest in First-In-Class Health Tech Platform Oncoshot SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company f...

Happy International Women’s Day from Oncoshot. We strive to foster gender equality today for a cancer-free tomorrow.

Together, we can do more and do better.

Are we doing enough about the human papillomavirus (HPV)?

Despite being one of the most preventable types of cancers since the introduction of HPV vaccines, the global incidence of cervical cancer is steadily rising, ranking as the 4th most common female cancer in the world.

today so we can deliver a world with

Today marks International Childhood Cancer Day (ICCD), a global cooperative effort to call attention to childhood cancer and communicate support to children, adolescents, and families going through this ordeal. The focus of ICCD 2022’s theme is on paying tribute to healthcare teams and the positive impact they have on the lives of children and adolescents with cancer.

Oncoshot hopes to build collaborative efforts with stakeholders from this field of cancer in the future to serve the community more effectively by easing the burden of trial matching for young ones.

Together, we can do more and do better.

--
#2022

Season’s Greetings,

We wish you a very Merry Christmas, a relaxing and joyful holiday season, and a Happy New Year full of excitement and possibility.

Warm wishes, Oncoshot

AstraZeneca Singapore signed a memorandum of understanding (MOU) with tech partners Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise on 25 November. The partnerships aim to pilot data and artificial intelligence-driven projects in Singapore to drive healthcare improvement.

"AstraZeneca's A.Catalyst Network brings together partners across the public and private sectors to unlock the power of innovation and transform care delivery for improved patient experience and outcomes", said country president Vinod Narayanan. "Facilitating such partnerships will drive improvement in the healthcare ecosystem while providing patients with access to new digital healthcare solutions that can revolutionise the management of challenging diseases such as cancer, diabetes, heart failure and respiratory diseases."

The partnership was witnessed by Singapore's Ministry of Health, the Government Offices of Sweden, the Embassy of Sweden in Singapore, and Business Sweden.

Check out the article here:
https://lnkd.in/gAFGA5x6

AstraZeneca SG signs MOU with tech partners AstraZeneca Singapore signed a memorandum of understanding (MOU) with tech partners Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise.

Extremely proud and excited for Oncoshot to be a partner with AstraZeneca Singapore for the Singapore-Sweden Digital Healthcare initiative.

Looking forward to joining forces with Respiree, Ubie, Thermascan Ltd and Hewlett Packard Enterprise in developing tomorrows healthcare ecosystem.

We're proud to be enabling a digitally-powered cancer clinical trial landscape poised to spur cutting-edge research, through the launch of InSite Feasibility.

Thank you Singapore Association of Pharmaceutical Industries for this wonderful shoutout. We hope to continue to build more meaningful partnerships to improve patients' access to innovative cancer therapies.

AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials - PR Newswire APAC SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials

Happy ! We're excited to announce the launch of InSite Feasibility, as well as our partnership with to accelerate cancer research.

As our commercial partner, the biopharmaceutical company will harness our InSite Feasibility platform to streamline the cancer trial enrolment process, thus allowing more Singaporeans to access cutting-edge therapies. Together, we can do more, and do better.

Oncoshot launches InSite Feasibility and partners AstraZeneca to streamline recruitment process for cancer clinical trials AstraZeneca will tap into Oncoshot’s data analytic capabilities of InSite Feasibility to introduce more relevant and innovative cancer clinical trials to Singapore. 

Did you know that patients with advanced-stage/metastatic non-small cell lung cancer who have undergone immunotherapy treatment using PD-1 inhibitors such as pembrolizumab and Nivolumab have shown an average five-year survival rate of up to 20 per cent?

This ongoing clinical trial explores whether the results can be improved with the use of a newly developed PD-1 inhibitor, in a three drug combination. Read on to find out if you are eligible for trial enrolment.

Dr Toh Chee Keong: zimberelimab trialled in new combination immunotherapy for PD-L1 positive metastatic non small cell lung cancer Similar PD-1 inhibitors have been shown to improve the five-year survival rate of patients with advanced non-small cell lung cancer.

Can Traditional Chinese Medicine help with cancer-related fatigue? Should I consume health supplements while undergoing breast cancer rehabilitation?

If you missed our webinar, held in collaboration with Breast Cancer Foundation, read on to answer your questions about improving your quality of life after breast cancer treatment and surgery. Our experts weigh in on how you can deal with post-surgery symptoms such as numbness, fatigue and lymphedema. And find clinical trials that explore new therapies for breast cancer survivors.

Breast cancer rehabilitation: post mastectomy physical therapy and more Experts including Dr Mothi Babu Ramalingam from Singapore General Hospital weighed in on breast cancer rehabilitation options in Singapore, including TCM.

Early detection of liver cancer can result in the difference between costly life-sustaining treatment and a cure. Yet, the disease is often diagnosed in its advanced stages, due to limitations to active surveillance. This ongoing study aims to change this and develop a more accurate, convenient method of detecting liver cancer early. Yes, you may be able to get a one-stop test at your local GP, and have your results the next week. Read our interview with the study's Principal Investigator here:

Prof Pierce Chow: ELEGANCE study explores cutting-edge methods to detect liver cancer early and more accurately The multi-centre Singapore study offers active surveillance to patients at high risk of developing liver cancer, with the aim of developing more accurate miRNA diagnostics for early HCC.

For patients with advanced-stage liver cancer who are deemed unsuitable for standard care, treatment options can be limited. This ongoing clinical trial explores a new combination therapy aimed at achieving progression-free survival for such patients. Read our exclusive interview with its principal investigator, Dr Choo Su Pin from Curie Oncology, here.

#

Dr Choo Su Pin: New combination therapy explores progression-free survival in advanced-stage HCC patients The therapy being trialled combines Toripalimab, an anti-PD1 immunotherapy drug developed in China, together with Bevacizumab.

Just two more days to register for our webinar on breast cancer rehabilitative care....

Our panel of speakers will be covering tips on how to manage your post-surgery symptoms and boost your recovery journey.
Sign up here: https://tinyurl.com/rehabcare

She dressed up as bat woman to lighten the mood during chemotherapy sessions, and practised mindfulness.

In the lead up to our upcoming webinar on breast cancer rehabilitative care, read about Breast Cancer Foundation member Amy Neary's emotional journey to recovery from breast cancer here:

Stage 3 breast cancer survivor: mental health support is crucial in recovery Tech professional Amy Neary drew on emotional support from her family, friends and Singapore’s Breast Cancer Foundation to cope with the rigorous treatments and surgeries, plus the toll they took on her mental well-being.

The journey after breast cancer treatment and surgery can be an uphill one. Tune in to our complimentary webinar to find out your rehabilitative care options, as well as how to manage post-surgery symptoms such as lymphedema.

Have your questions answered by the experts during our live Q&A session. Register for the event at https://tinyurl.com/rehabcare

Can Traditional Chinese Medicine (TCM) be used in a clinical setting to help improve cancer survivors' quality of life? Read our interview with the principal investigator of this ongoing study being conducted at National Cancer Centre Singapore that explores the safety and efficacy of TCM to alleviate cancer-related fatigue.

Dr Tira Tan: HERBAL trial explores improving cancer survivors’ quality of life through TCM The Phase II, randomised, double-blinded, placebo-controlled trial, which is being conducted at NCCS, evaluates the safety and efficacy of the Xiang Bei Yang Rong Tang decoction in reducing cancer related fatigue.

Talk about ending the week on a high. Being named a winner at Singapore Business Review National Business Awards 2021 for the Health Products and Services category certainly validates our efforts towards catalysing cutting edge cancer research and widening cancer patients' treatment options through clinical trials.

Stay tuned for more exciting news ahead, as we continue working towards supporting Singapore's cancer ecosystem through technology.

Oncoshot named winner at Singapore Business Review National Business Awards 2021 Oncoshot was recognised as winner for the Health Products & Services category, for its commitment to elevate cancer treatment through technology.

Some interesting news in the fast developing field of immunotherapy: A global study being conducted in Singapore - among other locations - is focused on combining immune checkpoint inhibitors and TACE therapy to achieve progression-free survival for liver cancer patients with earlier-stage HCC.

Read on to find out if any of your patients qualify for the clinical trial, and sign up with Oncoshot to discover more ongoing cancer studies such as this.

Dr Choo Su Pin on ongoing Phase III EMERALD-1 study for cancer patients with intermediate stage HCC The global study explores the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE with durvalumab plus bevacizumab therapy.

We are excited to be featured, alongside the other winners of the ORIGIN Innovation Awards 2020, in this piece on tech innovation in the healthcare industry. Thank you, TechNode Global, for recognising Oncoshot's efforts to transform the oncology clinical trial space and elevate cancer care.

Here's their interview with our co-founder, Dr Huren Sivaraj:

ORIGIN: How tech startups take advantage of data and intelligence in enhancing the delivery of healthcare services - TechNode Global HealthTech startups are enhancing partnerships within the industry and with end-users, thus providing more value in health and wellness initiatives.

Precision oncology calls for innovative solutions to help improve cancer patient's outcomes. An ongoing pilot study led by Prof Dean Ho and Dr Raghav Sundar from National University of Singapore and National University Health System is exploring harnessing Artificial Intelligence technology to inform guided dosing for treating solid tumours.

Read our interview with the study's two principal investigators, who share on how they aim to bridge innovation and clinical implementation by bringing together multiple stakeholders.

PRECISE CURATE.AI trial: Dr Dean Ho and Dr Raghav Sundar on pilot study exploring guided dosing with XELOX, XELIRI and single agent capecitabine to treat solid tumours The Phase I and II single-arm pilot study with multiple cohorts of patient populations harnesses AI for personalised guidance of an individual’s dose modulations based only on his/her data. It aims to re-look at the way oncology clinical trials are designed.